431
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Daiichi Sankyo's recently active trials. Comparator arms are excluded.
- Trastuzumab deruxtecan10 trials
- Trastuzumab deruxtecan6 trials
- Bempedoic acid6 trials
- Ezetimibe6 trials
- No drug6 trials
- HER3-DXd6 trials
Upcoming readouts
Next primary completion dates among Daiichi Sankyo's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Aug 2026A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)Phase 3
- Apr 2027IDeate-Lung02: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapse…Phase 3
- Sept 2027A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsPhase 2
- Oct 2027Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Recept…Phase 3
- Feb 2028A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovaria…Phase 2
- Jun 2028Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positi…Phase 3
Top therapeutic areas
Conditions studied most often across Daiichi Sankyo's recently active trials.
- Advanced Solid Tumor10 trials
- Breast Cancer8 trials
- Non-small Cell Lung Cancer6 trials
- Mixed Dyslipidemia4 trials
- Advanced Cancer4 trials
- Metastatic Solid Tumor3 trials
Daiichi Sankyo trials
The 50 most significant of Daiichi Sankyo's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)NCT06812117No Drug | — | Not yet scored | OngoingActive, not recruiting | 721 est. | 24 Jul 2026 |
| A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)NCT06174987T-DXd | Phase 3 | Locked · track to reveal | OngoingRecruiting | 50 est. | 3 Aug 2026 |
| Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)NCT04704934Trastuzumab deruxtecan | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 490 est. | 31 Aug 2026 |
| A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)NCT06362252Ifinatamab deruxtecan | Phase 1 | Locked · track to reveal | OngoingRecruiting | 123 est. | 30 Sept 2026 |
| First-in-Human Study of DS-3939a in Participants With Advanced Solid TumorsNCT05875168DS-3939a | Phase 1 | Locked · track to reveal | OngoingRecruiting | 590 est. | 20 Oct 2026 |
| MILOSTreatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed DyslipidemiaNCT04579367Bempedoic acid and/or its fixed-dose combination with ezetimibe | — | Not yet scored | OngoingActive, not recruiting | 5,000 est. | 30 Oct 2026 |
| Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic ImpairmentNCT06740799Quizartinib | Phase 1 | Locked · track to reveal | OngoingRecruiting | 12 est. | 31 Oct 2026 |
| A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)NCT05993234Trastuzumab deruxtecan | — | Locked · track to reveal | OngoingRecruiting | 257 est. | 1 Dec 2026 |
| First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)NCT03401385Datopotamab Deruxtecan (Dato-DXd) | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 890 est. | 1 Jan 2027 |
| Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular DystrophyNCT04433234DS-5141b | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 8 est. | 31 Jan 2027 |
| RERUNClinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)NCT06809764No drug | — | Locked · track to reveal | OngoingRecruiting | 150 est. | 12 Feb 2027 |
| IDeate-Lung02A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerNCT06203210Ifinatamab deruxtecan | Phase 3 | Locked · track to reveal | OngoingRecruiting | 540 est. | 30 Apr 2027 |
| Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant TumorsNCT04145622Ifinatamab deruxtecan (I-DXd) | Phase 1 | Locked · track to reveal | OngoingRecruiting | 250 est. | 30 Apr 2027 |
| Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the BloodNCT03793478Quizartinib | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 65 est. | 1 May 2027 |
| A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid TumorsNCT04419532DS-1055a | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 40 est. | 1 Jul 2027 |
| TRICONOSA Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed DyslipidemiaNCT06686615Bempedoic acid | — | Not yet scored | OngoingRecruiting | 2,000 est. | 31 Jul 2027 |
| RECOVERReal-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaNCT06846996Trastuzumab deruxtecan (T-DXd) | — | Locked · track to reveal | OngoingRecruiting | 260 est. | 31 Jul 2027 |
| A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478HER3-DXd | Phase 2 | Locked · track to reveal | OngoingRecruiting | 740 est. | 1 Sept 2027 |
| A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)NCT06660654Raludotatug deruxtecan | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 200 est. | 30 Sept 2027 |
| Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast CancerNCT05950945Trastuzumab Deruxtecan | Phase 3 | Locked · track to reveal | OngoingRecruiting | 250 est. | 1 Oct 2027 |
| First-in-Human Trial of DS1025a in Participants With Advanced Solid TumorsNCT07681882DS1025a | Phase 1 | Not yet scored | OngoingNot yet recruiting | 45 est. | 21 Jan 2028 |
| A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT07244341Valemetostat | Phase 1 | Locked · track to reveal | OngoingRecruiting | 60 est. | 31 Jan 2028 |
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube CancerNCT06161025R-DXd | Phase 2 | Locked · track to reveal | OngoingRecruiting | 860 est. | 29 Feb 2028 |
| A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate CancerNCT07189403DS9051b | Phase 1 | Locked · track to reveal | OngoingRecruiting | 40 est. | 1 Mar 2028 |
| A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)NCT06210776Trastuzumab deruxtecan | — | Locked · track to reveal | OngoingRecruiting | 800 est. | 1 Mar 2028 |
| A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic AlterationsNCT06644768valemetostat tosylate | Phase 1 | Locked · track to reveal | OngoingRecruiting | 137 est. | 30 Mar 2028 |
| Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerNCT06731478Trastuzumab Deruxtecan | Phase 3 | Locked · track to reveal | OngoingRecruiting | 726 est. | 1 Jun 2028 |
| A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)NCT06644781Ifinatamab deruxtecan | Phase 3 | Locked · track to reveal | OngoingRecruiting | 510 est. | 1 Jun 2028 |
| A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular EventsNCT07474649Bempedoic acid | Phase 3 | Locked · track to reveal | OngoingNot yet recruiting | 103 est. | 1 Jun 2028 |
| Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete RemissionNCT06824168Quizartinib High Dose | Phase 2 | Locked · track to reveal | OngoingRecruiting | 130 est. | 6 Jun 2028 |
| A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)NCT06330064Ifinatamab deruxtecan | Phase 2 | Locked · track to reveal | OngoingRecruiting | 520 est. | 25 Jul 2028 |
| A Study of DS3610a in Participants With Advanced Solid TumorNCT07159126DS3610a | Phase 1 | Locked · track to reveal | OngoingRecruiting | 70 est. | 1 Sept 2028 |
| MusashiA Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed DyslipidaemiaNCT07206472Combination of bempedoic acid and ezetimibe | — | Not yet scored | OngoingActive, not recruiting | 2,560 est. | 1 Sept 2028 |
| DO-01Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)NCT06819007Trastuzumab Deruxtecan | Phase 3 | Locked · track to reveal | OngoingRecruiting | 582 est. | 1 Nov 2028 |
| A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid TumorsNCT06244485Valemetostat tosylate | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 98 est. | 1 Nov 2028 |
| First-in-Human Trial of DS-2243a in Participants With Advanced Solid TumorsNCT06644755DS-2243a | Phase 1 | Locked · track to reveal | OngoingRecruiting | 150 est. | 30 Nov 2028 |
| A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid TumorsNCT07015697Trastuzumab Deruxtecan | Phase 1 | Locked · track to reveal | OngoingRecruiting | 76 est. | 31 Dec 2028 |
| Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)NCT05555732Datopotamab Deruxtecan | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 1,170 est. | 11 May 2029 |
| Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial CarcinomaNCT07129993Dato-DXd | Phase 2 | Locked · track to reveal | OngoingRecruiting | 630 est. | 1 Jun 2029 |
| TROPION-Lung08Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsNCT05215340Datopotamab Deruxtecan | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 740 est. | 4 Mar 2030 |
| A Study of DS5361b in Participants With Advanced Solid TumorsNCT07182591DS5361b | Phase 1 | Locked · track to reveal | OngoingRecruiting | 192 est. | 18 Mar 2030 |
| DESTINY-Lung06Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerNCT06899126Trastuzumab Deruxtecan | Phase 3 | Locked · track to reveal | OngoingRecruiting | 686 est. | 24 Apr 2030 |
| A Study of DS-1103a Combination Therapy in Participants With Advanced Solid TumorsNCT05765851DS-1103a | Phase 1 | Locked · track to reveal | OngoingRecruiting | 108 est. | 15 May 2030 |
| QuANTUM-WILDQuizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLNCT06578247Quizartinib | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 700 est. | 26 Jun 2030 |
| DB-GuideT-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdNCT07683754Trastuzumab deruxtecan | Phase 3 | Locked · track to reveal | OngoingNot yet recruiting | 200 est. | 4 Jul 2030 |
| A First-in-Human Trial of DS3790a in Participants With Hematological MalignanciesNCT07220616DS3790a | Phase 1 | Locked · track to reveal | OngoingRecruiting | 420 est. | 30 Nov 2030 |
| DESTINY Breast Respond HER2-(Ultra)Low EuropeNCT05945732Trastuzumab deruxtecan | — | Locked · track to reveal | OngoingRecruiting | 2,295 est. | 31 Dec 2030 |
| A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast CancerNCT07701941Patritumab deruxtecan | Phase 1 | Locked · track to reveal | OngoingNot yet recruiting | 220 est. | 1 Jan 2031 |
| Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial CancerNCT07022483Trastuzumab Deruxtecan | Phase 3 | Locked · track to reveal | OngoingRecruiting | 710 est. | 23 Mar 2032 |
| A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) TreatmentNCT04635111TURALIO™ | — | Not yet scored | OngoingRecruiting | 30 est. | 1 Jun 2036 |